LCI699
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cushing Syndrome
Conditions
Cushing Syndrome
Trial Timeline
Apr 28, 2021 → Jul 21, 2027
NCT ID
NCT03708900About LCI699
LCI699 is a phase 2 stage product being developed by Recordati for Cushing Syndrome. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03708900. Target conditions include Cushing Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03708900 | Phase 2 | Recruiting |
Competing Products
20 competing products in Cushing Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD4017 and prednisolone + Placebo Oral Tablet and prednisolone | AstraZeneca | Phase 2 | 52 |
| Pasireotide with or without cabergoline | Novartis | Phase 2 | 52 |
| osilodrostat + LCI699 matching placebo | Novartis | Phase 3 | 77 |
| pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mg | Novartis | Phase 3 | 77 |
| LCI699 | Novartis | Phase 2 | 52 |
| Pasireotide sub-cutaneous | Novartis | Phase 3 | 77 |
| osilodrostat + osilodrostat Placebo | Novartis | Phase 3 | 77 |
| Osilodrostat | Novartis | Phase 2 | 52 |
| Pasireotide | Novartis | Phase 3 | 77 |
| Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + Metformin | Novartis | Approved | 85 |
| Pasireotide | Novartis | Phase 2 | 52 |
| SOM230 s.c. | Novartis | Phase 2 | 52 |
| Lu AG13909 | Lundbeck | Phase 2 | 49 |
| Osilodrostat | Recordati | Pre-clinical | 20 |
| Intervention/Treatment | Recordati | Approved | 82 |
| Pasireotide | Recordati | Pre-clinical | 20 |
| Pasireotide + Cabergoline + Pasireotide LAR | Recordati | Approved | 82 |
| Osilodrostat | Recordati | Pre-clinical | 20 |
| osilodrostat | Recordati | Phase 2 | 49 |
| Osilodrostat | Recordati | Pre-clinical | 20 |